Wales has recorded one new coronavirus-related death and just 30 confirmed cases in the last 24 hours.

The latest data, published by Public Health Wales on Tuesday, May 11, brings the overall number of positive cases since the pandemic began to 211,961.

The total number of people to have died with coronavirus in Wales is now 5,557.

The seven-day infection rate across Wales as a whole now stands at 8.8, based on the number of new infections confirmed per 100,000 population in the week up to May 6 - a slight rise from 8.6 on Monday.

In terms of tests, the percentage coming back with positive results is now down to 0.9% – below 1% for the first time in months and significantly below the key benchmark of 5%.

Uptake of the first vaccine dose by priority group (according to PHW):

  • Care home residents: 14,882 (97.8%)
  • Care home workers: 34,671 (90.9%)
  • 80 years and older: 165,981 (95.6%)
  • Healthcare workers: 135,115 (94.7)
  • Social care workers: 45,326 (no percentage available)
  • 75-79 years: 128,022 (96.3%)
  • 70-74 years: 175,555 (95.7%)
  • Clinically extremely vulnerable 16-69 years: 75,876 (93.3%)
  • 65-69 years: 169,578 (94%)
  • Clinical risk groups 16-64 years: 303,424 (85.7%)
  • 60-64 years: 188,343 (91.5%)
  • 55-59 years: 208,624 (89.2%)
  • 50-54 years: 198,466 (87%)
  • 40-49 years: 302,797 (77.1%)
  • 30-39 years: 222,455 (52.8%)
  • 18-29 years: 159,967 (34.2%)

Uptake of the second vaccine dose by priority group (according to PHW):

  • Care home residents: number 13,729 (90.2%)
  • Care home workers: 30,228 (79.3%)
  • 80 years and older: 157,023 (90.5%)
  • Healthcare workers: 119,545 (83.8%)
  • Social care workers: 38,760 (no percentage available)
  • 75-79 years: 121,806 (91.7%)
  • 70-74 years: 165,646 (90.3%)
  • Clinically extremely vulnerable 16-69 years: 64,583 (79.4%)
  • 65-69 years: 107,113 (59.4%)
  • Clinical risk groups 16-64 years: 39,379 (11.1%)
  • 60-64 years: 51,460 (25%)
  • 55-59 years: 47,221 (20.2%)
  • 50-54 years: 41,856 (18.3%)
  • 40-49 years: 59,462 (15.1%)
  • 30-39 years: 49,393 (11.7%)
  • 18-29 years: 39,979 (8.5%)

In total 1,948,683 people have had a first vaccine dose while 854,441 people so far have had the full two-dose course.

Cardiff reported the most new virus cases on Tuesday with six, followed by Caerphilly with five and Swansea with three.

Meanwhile Monmouthshire, Vale of Glamorgan, Carmarthenshire and Ceredigion had two cases, while Blaenau Gwent, Newport, Flintshire, Bridgend, Merthyr Tydfil, RCT, Powys and Neath Port Talbot had one each.

Seven local authorities reported zero cases including Torfaen, Anglesey, Conwy, Denbighshire, Gwynedd, Wrexham and Pembrokeshire.

Cases per 100,000 based on seven-day rolling average (April 29 to May 5)

Aneurin Bevan University Health Board

Blaenau Gwent: 1.4 (down from 2.9)

Newport: 25.2 (up from 22)

Caerphilly: 5.5 (down from 7.2)

Torfaen: 6.4 (down from 8.5)

Monmouthshire: 6.3 (down from 8.5)

Betsi Cadwaladr University Health Board

Conwy: 3.4 (down from 4.3)

Anglesey: 4.3 (unchanged)

Gwynedd: 9.6 (up from 7.2)

Denbighshire: 5.2 (up from 3.1)

Flintshire: 6.4 (down from 7)

Wrexham: 12.5 (down from 16.9)

Cardiff and Vale University Health Board

Cardiff: 15 (up from 12.5)

Vale of Glamorgan: 6 (up from 5.2)

Cwm Taf Morgannwg University Health Board

Merthyr Tydfil: 6.6 (up from 3.3)

Rhondda Cynon Taf: 6.2 (down from 7)

Bridgend: 2.7 (down from 4.1)

Hywel Dda University Health Board

Carmarthenshire: 9.5 (up from 6.4)

Pembrokeshire: 14.3 (down from 15.9)

Ceredigion: 8.3 (up from 6.9)

Powys Teaching Health Board

Powys: 11.3 (up from 9.1)

Swansea Bay University Health Board

Neath Port Talbot: 4.9 (down from 5.6)

Swansea: 4.9 (down from 6.1)

Wales total: 8.8 (up from8.6)

Sign up to The Coronavirus Briefing, WalesOnline's daily coronavirus newsletter, to get the latest Covid-19 updates sent straight to your inbox.

The Coronavirus Briefing features WalesOnline's best and most important stories about how Covid-19 is affecting people, business, politics and Welsh life. From the latest lockdown announcements to infection rates, vaccine news and more, you'll never miss an important story again.

Now more than ever this sort of journalism matters and we want you to be able to access it all in one place with one click. It's completely free and you can unsubscribe at any time.

It takes just seconds to sign up - simply click here, enter your email address and tick the box for The Coronavirus Briefing.

Dr Giri Shankar, incident director for the novel coronavirus outbreak response at Public Health Wales, said: "The variant B.1.617.2, one of the variants first identified in India, has been designated as a Variant of Concern (VOC21APR-02) due to its high transmissibility, which is comparable to the Kent variant. There is no evidence of wider community transmission of this variant in Wales, and the Kent variant remains the dominant strain here.

"Coronavirus cases by variant in Wales are reported on the UK Government website.

"On Friday, May 7, the Joint Committee on Vaccination and Immunisation (JCVI) updated its advice on the use of the Covid-19 Oxford/AstraZeneca vaccine for people aged under 40. JCVI advice is followed in Wales.

"The advice states that unvaccinated adults aged 30-39 years who are not in a clinical priority group because of long term health conditions, should where possible be offered an alternative to the AstraZeneca Covid-19 vaccine, where it would not significantly delay vaccination.

"JCVI is not advising against using AstraZeneca vaccine in 30-39 year olds, only that other vaccines are preferred. JCVI advise that anyone who has already received a first dose of AstraZeneca should continue to receive the same vaccine for their second dose, there are no clotting safety concerns with the second dose. It is the second dose which gives stronger and longer protection. Our statement in response to the latest advice is available to view on our website.

"JCVI also recently advised that pregnant women should be offered the Covid-19 vaccine at the same time as the rest of the population, based on their age and clinical risk group."